Leadership Overview
Themis Medicare has 5 executives leading key functions including financial strategy, information technology, corporate governance, domestic operations, and international business development.
Committed to advancing global health through pharmaceutical innovation, Themis Medicare delivers high-quality medicinal solutions for cardiology, pain management, and anti-infectives while maintaining a robust manufacturing presence across the Indian market.
Committed to advancing global health through pharmaceutical innovation, Themis Medicare delivers high-quality medicinal solutions for cardiology, pain management, and anti-infectives while maintaining a robust manufacturing presence across the Indian market.
Leadership Roles at Themis Medicare
Tushar Dalal - Chief Financial Officer
Tushar Dalal, the Chief Financial Officer at Themis Medicare, directs all fiscal planning and capital allocation strategies. Overseeing the financial health of the organization, the Chief Financial Officer ensures rigorous compliance with regulatory standards while optimizing resource distribution across manufacturing units. Dalal manages long-term investment portfolios to support the development of cardiology and pain management pharmaceuticals. By analyzing market trends, the Chief Financial Officer identifies opportunities for cost efficiency and revenue growth within the competitive pharmaceutical landscape. Tushar Dalal maintains close collaboration with the Board to provide transparent reporting on fiscal performance. This leadership role involves mitigating financial risks associated with raw material procurement and global supply chain fluctuations. Through precise budgetary oversight, the Chief Financial Officer strengthens the overall market position of the company, ensuring sustainable growth and profitability for all stakeholders involved in the production of medicinal chemicals.
Prakash Naringrekar - Chief Financial Officer & Company Secretary
Prakash Naringrekar, the Chief Financial Officer & Company Secretary at Themis Medicare, manages corporate governance and legal compliance alongside financial reporting. Overseeing the administrative framework, the Chief Financial Officer & Company Secretary ensures that all board activities align with statutory requirements and corporate bylaws. Naringrekar directs the preparation of financial statements and coordinates with external auditors to maintain institutional integrity. By facilitating transparent communication between the leadership team and shareholders, the Chief Financial Officer & Company Secretary upholds the ethical standards of the organization. Prakash Naringrekar monitors legislative changes affecting the pharmaceutical industry to mitigate legal risks and ensure operational continuity. This leadership role involves managing corporate records and overseeing the execution of strategic board decisions. Through meticulous attention to regulatory detail, the Chief Financial Officer & Company Secretary provides the structural stability necessary for the company to focus on manufacturing excellence and the expansion of its diverse medicinal product portfolio.
Muraridutt Sharma - President
Muraridutt Sharma, the President at Themis Medicare, directs the overarching strategic vision and domestic operational execution. Overseeing the manufacturing of pharmaceuticals and medicinal chemicals, the President ensures that all production processes meet stringent quality standards for cardiology and pain management products. Sharma coordinates with department heads to optimize supply chain logistics and enhance market penetration within the domestic sector. By fostering a culture of innovation, the President drives the development of new health and nutrition solutions to meet evolving patient needs. Muraridutt Sharma maintains alignment between daily operations and the long-term mission of the company. This leadership role involves managing cross-functional teams to improve manufacturing throughput and operational efficiency. Through consistent focus on product quality and market responsiveness, the President strengthens the reputation of the company as a leader in the pharmaceutical industry, ensuring that all medicinal offerings provide maximum value to the healthcare community.
Hoshang Messman - President, International Business Development
Hoshang Messman, the President, International Business Development at Themis Medicare, directs the expansion of the company footprint into global markets. Overseeing international partnerships, the President, International Business Development identifies new opportunities for exporting medicinal chemicals and pharmaceutical products to diverse regions. Messman manages cross-border regulatory requirements and negotiates distribution agreements to increase the global reach of the company. By analyzing international market dynamics, the President, International Business Development tailors the product portfolio to address specific regional health needs in cardiology and anti-infectives. Hoshang Messman collaborates with local distributors to ensure the effective delivery of health and nutrition products across international borders. This leadership role involves navigating complex trade environments to secure sustainable growth outside the domestic market. Through strategic outreach and relationship management, the President, International Business Development elevates the global profile of the company, ensuring that high-quality pharmaceutical solutions reach patients in various international territories.
Reena Patel - Chief Information Officer
Reena Patel, the Chief Information Officer at Themis Medicare, architects the digital infrastructure supporting pharmaceutical manufacturing and data management. Overseeing the integration of advanced analytics, the Chief Information Officer drives the modernization of internal systems to improve operational efficiency across all production facilities. Patel manages cybersecurity protocols to protect proprietary research and development data related to anti-infectives and haematinics. By implementing scalable cloud solutions, the Chief Information Officer enables seamless communication between research labs and manufacturing plants. Reena Patel collaborates with executive leadership to align technological investments with the broader mission of delivering high-quality health and nutrition products. This role involves streamlining data workflows to accelerate the time-to-market for new medicinal formulations. Through the deployment of robust enterprise software, the Chief Information Officer ensures that the company maintains a competitive edge in the digital era of pharmaceutical manufacturing and global distribution.
Explore Leadership Teams in Manufacturing
Established in 1978 and headquartered in London, Hikma Pharmaceuticals is a multinational pharmaceutical company that manufactures branded and non-branded generic and in-licensed pharmaceutical products.
Company Leadership
CS
TD
AK
OneSource Specialty Pharma Limited is a multimodal specialty pharmaceutical contract development and manufacturing organization headquartered in Bengaluru, India. Formed through the merger of three CDMO businesses within the Strides Group, specifically Stelis Biopharma's Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, OneSource was officially launched at CPHI Milan in 2024. The company operates five state-of-the-art manufacturing facilities in Bengaluru, all approved by major regulatory bodies including the US FDA, European Union authorities, and the Therapeutic Goods Administration. With over 30 years of manufacturing and quality excellence, OneSource employs more than 1,200 professionals, including over 200 techno-commercial experts, and serves more than 50 global pharmaceutical and biotechnology clients. The company specializes in end-to-end capabilities across multiple technology platforms and therapeutic modalities, including biologics drug substance and drug product manufacturing, drug-device combinations such as prefilled syringes and autoinjectors, complex sterile injectables, and soft gelatin capsules. OneSource has the capacity to produce over 100 million injectable doses and 2.4 billion soft gelatin capsules annually, with its flagship Bangalore site being one of the few facilities globally capable of manufacturing both biologics drug substance and drug product on the same premises. The company holds 35 approved Abbreviated New Drug Applications and has 19 commercialized drug products in the United States. Led by CEO Neeraj Sharma and Chief Quality Officer Bernhard Thurnbauer, OneSource is positioned to capitalize on growing demand for GLP-1 drug-device combinations and supply chain diversification driven by the BIOSECURE Act, projecting 32 percent revenue growth in 2025 with sales expected to reach 400 million dollars by 2028.
Company Leadership NS
SN
BM
Alkermes is a global biopharmaceutical enterprise that specialises in developing and commercialising innovative medicines for people living with complex psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company combines deep neuroscience expertise with patient‑inspired science to pursue treatments for conditions such as addiction, schizophrenia, bipolar disorder, opioid dependence and other central nervous system diseases. Its approach integrates scientific research, clinical development and specialised commercial infrastructure to deliver both marketed medicines and investigational candidates, aiming to address serious unmet medical needs and improve how chronic neurological and mental health conditions are managed.
Company Leadership
SS
Shionogi & Co., Ltd. is a Japanese pharmaceutical company dedicated to developing innovative treatments that improve patient lives worldwide. With a longstanding focus on addressing pressing global health challenges, the company has been a pioneer in discovering and delivering novel therapies for infectious diseases, including antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. Shionogi combines in-house research and development with strategic collaborations across industry, government agencies, biotech companies, and academic institutions to accelerate the advancement of its scientific programs and bring meaningful therapies to patients with urgency and precision.
Company Leadership TK
TN
MF
Frequently Asked Questions Regarding Themis Medicare Top Executives and Leadership Team
